Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Bremelanotide did not enhance sexual reward or affect melanocortin receptor expression in female Syrian hamsters, suggesting limited understanding of its neurobiological action.
Where it sits
this study against the rest of the pt-141 (bremelanotide) corpusSummary and findings
This study investigated the effects of bremelanotide on melanocortin receptor expression in the mesolimbic dopamine system and sexual reward using a female Syrian hamster model. The study found no effect of bremelanotide on receptor expression or enhancement of sexual reward. The findings contribute to understanding the neurobiological mechanisms of bremelanotide in the context of hypoactive sexual desire disorder.
Abstract
Hypoactive sexual desire disorder (HSDD) is the most reported sexual dysfunction among premenopausal women worldwide. Bremelanotide, trade name Vyleesi, has been approved by the United States Food and Drug Administration to treat HSDD. However, despite approval, very little is known about its neurobiological mechanism of action. In this study, we utilized a female Syrian hamster model to investigate the effects of bremelanotide on melanocortin receptor expression in the mesolimbic dopamine system and sexual reward. We found that the majority of melanocortin 3 and 4 (MC4R) receptor mRNA is expressed in dopamine neurons in the ventral tegmental area (VTA). Fewer neurons express MC4R in the nucleus accumbens (NAc) or dorsal striatum, where they rarely colocalize with neurons expressing dopamine D1 or D2 receptors. Instead, MC4R mRNA is expressed in nucleus accumbens interneurons. Neither the low nor the high dose of bremelanotide had an effect on the expression of melanocortin receptor mRNA in the mesolimbic dopamine system. Finally, sexual experience resulted in a conditioned place preference (CPP) in female Syrian hamsters, though bremelanotide treatment failed to enhance sexual reward in this test. The results of this study are discussed in conjunction with similar studies in rats, with the conclusion that bremelanotide does not act on the VTA-NAc reward circuit and does not enhance the rewarding effects of sexual interactions.
Background
The paper addresses the biological mechanisms underlying female hypoactive sexual desire disorder (HSDD) and evaluates bremelanotide, an FDA-approved treatment. Prior research has indicated varying efficacy and safety profiles for treatments targeting sexual desire. This study is significant as it explores the drug's effects in a preclinical model, potentially informing future human studies.
Methods
The study employed a rodent model using female Syrian hamsters to assess the effects of bremelanotide. The specific sample size, dosage, duration of administration, and primary versus secondary outcome measures were not reported in the abstract.
Results
Not reported in abstract.
Interpretation
Without specific numeric findings, it is challenging to compare the results to existing literature or assess the clinical significance of the effects observed. The lack of detailed outcomes limits the ability to draw firm conclusions about the drug's efficacy in this model. The findings may suggest areas for further research but should be interpreted cautiously due to the preclinical nature of the study.
Key findings
- Not reported in abstract.
Limitations
- Rodent model may not translate to humans.
- Specific numeric findings not reported.
- Sample size not disclosed.
- Lacks detailed methodology in abstract.